Cannabis Law Report

AUGUST 2, 2021

Study Results Indicate SCI-160 Has A Significant Analgesic Effect on Acute and Chronic Pain. Daily injections of SCI-160 significantly alleviate pain in a hind paw incision model of post-surgical pain up to 4 days post surgery as compared with vehicle treated animals. TEL AVIV, Israel , Aug. ” About The Study.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

JUNE 8, 2021

Inflammation has specifically been implicated in the pathophysiology of Parkinson’s Disease, chronic pain, and bipolar disorder. A better understanding of the anti-inflammatory effects of psilocybin has potential to allow for optimization and personalization of psilocybin treatment.”. About Silo Pharma. Silo Pharma. Brett Maas.

Patients 92

Patients Research and Development Clinical Trials Chronic Pain 92

Cannabis Law Report

NOVEMBER 26, 2019

In Canada today, close to 70% of all those surveyed aged 19+ believe that cannabis is an alternate form of treatment to some medical conditions according to Vividata’s Vivintel , the nation’s largest syndicated cannabis consumer study. We are partnering with Canopy Growth to offer a unique event of fun and canna-learning.

Chronic Pain 91

Chronic Pain Events THC Education 91

Cannabis Law Report

JANUARY 12, 2022

“This is a landmark event for Gb Sciences,” said Chairman and CEO John Poss. and three international patents that have been issued to protect therapeutic mixtures for Parkinson’s disease, chronic pain, hyperinflammation, and heart disease. .” In addition, Gb Sciences has 12 U.S.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

JUNE 23, 2021

The analysis of patient-reported outcome measures following treatment with cannabis-based medicinal products (CBMPs) in a study covering patients with all conditions found statistically significant improvements in anxiety, sleep , and general quality of life at one, three, and six months following treatment, compared to baseline assessment.

Cannabinoids 59

Cannabinoids Data Chronic Pain Sleep 59

LifeCannMD

DECEMBER 13, 2021

On January 3, 2017, Amendment 2 came into effect in Florida allowing for the legal medicinal use of cannabis.The rules for use and administration are outlined in Senate Bill 8A of The Florida Medical Marijuana Legalization Initiative which allows for treatment of “diagnosable, debilitating conditions.” Chronic nonmalignant pain.

Conditions 52

Conditions Chronic Pain Marijuana Patients 52

Cannabis Law Report

OCTOBER 17, 2019

Tree of Knowledge will be introducing chronic pain management protocols and research into the Caribbean market. The introduction of these protocols will take the form of clinical trials and research that will include the usage of specific strains of cannabis that aid in chronic pain and cancer treatments.

Clinical Trials 40

Clinical Trials Research and Development Chronic Pain CBD 40

MMJ Recs

APRIL 30, 2022

In some cases, there are events known as patient drives that can make the process even easier for qualifying individuals to get their recommendation and access medical marijuana. The certification process is same-day, meaning each patient can gain access to MMJ treatment the day of their appointment through the patient drive.

Patients 52

Patients Dispensary Chronic Pain Access 52

MMJ Recs

OCTOBER 2, 2023

California has been a trailblazer in the realm of medical marijuana, offering patients access to a variety of treatment options. If the doctor determines that medical cannabis is a suitable treatment option, they will provide a recommendation for the patient. In 1996, the state became the first in the U.S.

Dispensary 52

Dispensary Patients Environment Conditions 52

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. “It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool.

Programs 108

Programs Research and Development Education Treatment 108

MMJ Recs

MARCH 2, 2024

Observing discretion in discussions regarding medical conditions and treatment enhances privacy and respect among patrons. A: Qualifying medical conditions in Ohio include cancer, PTSD, chronic pain, epilepsy, and more. Additionally, adhering to dispensary policies on product handling and consumption promotes harmony and safety.

Dispensary 52

Dispensary Patients Marijuana Education 52

Cannabis Law Report

NOVEMBER 9, 2021

(“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a modern world, today announced the official, completed acquisition of Ketamine Wellness Centers Arizona LLC (“KWC”), becoming the largest chain of wellness centers providing ketamine treatments in the U.S.

Treatment 52

Treatment Therapy Media Access 52

MMJ Recs

MARCH 25, 2022

Patient drives are like pop-up day events, during which many people can avail of quick and easy appointments for MMJ cards if they have a qualifying condition. There may be other qualifying conditions for a NY MMJ card. These can be discussed during your consultation with a licensed MMJRecs NY state physician.

Patients 52

Patients Conditions Chronic Pain Dispensary 52

Cannabis Law Report

DECEMBER 8, 2021

Single-dose transdermal delivery of Epoladerm was well-tolerated in all minipigs and no treatment-related clinical observations, changes in body weight, or dermal irritation were observed. Probudur™ is a single injection long-acting liposomal bupivacaine formulation being developed to manage post-operative pain. Christopher M.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

Cannabis Law Report

NOVEMBER 26, 2021

In the event that manufacturing costs from Canada become materially higher than the cost to produce in Colombia, FloVaria will explore moving its supply chain activities of Avaria products to Flora Lab. The results showed that all volunteers felt improvement in pain or were free of pain within two minutes of application of K6XPR, where 52.1%

Wellness and Beauty 52

Wellness and Beauty Supply Chain Research and Development Events 52

MedicalJane

DECEMBER 13, 2017

These changes included adding chronic pain and PTSD to its list of qualifying medical conditions. Chronic pain, on its own, is already responsible for more than 7,500 new patients joining New York’s MMJ program. who sponsored the 2014 law that legalized medical marijuana in New York. Diane Savino (D-S.I.),

Programs 49

Programs Patients Chronic Pain Marijuana 49

The Cannigma

OCTOBER 8, 2021

The laws on cannabis are covered in the country’s Misuse of Drugs Act of 1971 which lists a litany of regulations covering cannabis and other drugs. The law states that it is also illegal for occupiers of premises to permit certain activities like smoking cannabis. What British law permits for medical patients.

Legalization 52

Legalization Medicine Conditions Patients 52

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients 98

Patients Education Marijuana Therapy 98

Otherside Farms

JANUARY 17, 2020

CBD is therefore convenient to those that suffer nausea from chemotherapy treatment and other conditions. Many benefits of CBD are now in the public domain, and even doctors recommend quality selections of its products to patients’ treatment of various ailments. It is so uncomfortable and disturbing when one is in pain.

Food 52

Food Research and Development Seed-To-Sale Vaping 52

Cannabis Law Report

AUGUST 24, 2021

. “Nearly 100,000 people in the United States have idiopathic pulmonary fibrosis (IPF), and although cases continue to climb, there is still a significant unmet need in treatment options for this chronic disease,” said Chris Chapman, M.D., President, Director and Chief Medical Officer. Investor Contact: Robert Schatz.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

NORML

MAY 24, 2019

The NORML FORML is a charitable event produced by Curved Papers for the benefit of NORML, Empire State NORML and CCA NORML, taking place in New York City during Cannabis Week in conjunction with the CWCBExpo, the city’s largest annual cannabis business trade show, which runs from May 29 – June 1 at the Javits Center. NORML FORML.

Chronic Pain 30

Chronic Pain Media Events Terpenes 30

Cannabis Law Report

DECEMBER 1, 2021

Because it can cross the blood-brain barrier and gain access to the central nervous system (CNS), MYMD-1 is also positioned to be a possible treatment for brain-related disorders. The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

DECEMBER 28, 2021

There were no treatment-related clinical observations, changes in body weight, or dermal irritation observed. Probudur™ Probudur is an injectable bupivacaine liposomal hydrogel for postoperative pain management which Virpax believes has improved onset and extended duration of action compared to existing treatment options.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

OCTOBER 6, 2021

The focus of this study will be on the use of cannabinoids in patients suffering from Fibromyalgia or chronic pain, with the primary research sites located in the United States and the United Kingdom. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. 1 (858) 264-6600.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

OCTOBER 19, 2021

MYMD-1’s primary purpose is to slow the aging process and extend healthy lifespan, and it is also showing promise as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Cannabis Law Report

OCTOBER 6, 2021

Probudur™ is a single injection long-acting liposomal bupivacaine formulation being developed to manage post-operative pain. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Christopher M. Chipman, CPA. Betsy Brod.

Research and Development 52

Research and Development Clinical Trials Pharmaceutical Chronic Pain 52

Cannabis Law Report

OCTOBER 17, 2019

Many experts believe it can lead to beneficial treatments, reiterated in a report released by the National Academies of Sciences, Engineering, and Medicine in January 2017. which aspects of the law are determined federally versus locally. which governmental bodies are responsible for regulating the law.

Law 40

Law Seed-To-Sale Hemp Recreational 40

Cannabis Law Report

MARCH 6, 2020

Europe is on the forefront of pharmaceutical development in the growing market for cannabinoid receptor target therapeutics which should bring further attention to our efforts in moving KLS-13019 forward for the treatment of neuropathic pain and other CNS disorders associated with neuroinflammation,” said Dean Petkanas , CEO of Kannalife.

Research and Development 59

Research and Development Marijuana Pharmaceutical Supply Chain 59

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. “It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool.

Programs 40

Programs Research and Development Education Treatment 40

Cannabis Law Report

SEPTEMBER 20, 2021

Lennox-Gastaut syndrome and Dravet syndrome are rare central nervous system diseases considered serious epileptic encephalopathies that cause different types of epileptic seizures as well as cognitive and behavioral changes and are generally resistant to treatment. Nanomerics has initiated preclinical studies of VRP324. Christopher M.

Epilepsy 52

Epilepsy Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

NOVEMBER 23, 2021

It’s also important to note that MYMD-1 shows promise in pre-clinical studies as a treatment for immune diseases including rheumatoid arthritis, multiple sclerosis, and Hashimoto’s thyroiditis, and as an anti-fibrotic and anti-proliferation therapeutic.”. MyMD Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

JANUARY 5, 2022

The issued claims protect the use of MYMD-1 in a method of treatment for the progressive and generalized loss of skeletal muscle mass and strength known as sarcopenia. MYMD-1 also shows promise in pre-clinical studies as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-proliferation therapeutic.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

SEPTEMBER 23, 2019

The AAFP urges its members to be involved in the diagnosis, treatment, and prevention of substance use, as well as secondary diseases impacted or caused by use. During the 20 th century, law enforcement and public policy activities have undermined opportunities for scientific exploration.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40

Cannabis Law Report

MAY 28, 2019

PUBLISHER: CANNABIS LAW REPORT. Veterans suffer widespread health problems including chronic pain, traumatic brain injuries, and post-traumatic stress disorder at a rate higher than the general population. Other common health problems include tinnitus, hearing loss, and lower-back pain. AUTHOR: Patrick McKnight.

Access 49

Access Marijuana Research and Development Programs 49

Cannabis Law Report

NOVEMBER 16, 2021

Our treatment designed for delaying aging has a distinctive drug profile of oral delivery, selectivity, and very low toxicity as compared with TNF blockers, all of which are delivered by injection only. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

MAY 6, 2022

Generally, a CBD product seller is expected (or required by law) to provide customers with access to a “certificate of analysis” or “COA” associated with specific products, which COA confirms the levels of CBD in products and upon which customers can rely. Taking CBD can relieve pain.”. “In

THC 52

THC CBD Media Food 52

Cannabis Law Report

NOVEMBER 15, 2021

Our lead product candidate is Envelta™, which utilizes MET to deliver enkephalin nanoparticles for acute and chronic pain including pain associated with cancer. Probudur™ is a single injection long-acting liposomal bupivacaine formulation being developed to manage post-operative pain. RECENT DEVELOPMENTS.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52